Day: February 18, 2025

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas (CPRIT) AUSTIN, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company,” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced today that it has closed a private placement with aggregate initial upfront proceeds of approximately $3.7 million and received a $2.0 million advance payment from CPRIT as part of its existing $17.6 million grant award. The funding from the private placement and the CPRIT advance will support the Company’s clinical development of Rhenium (186Re) Obisbemeda for leptomeningeal metastases...

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE:WSO) announced that its Board of Directors approved an 11% increase in its annual dividend to $12.00 per share on each outstanding share of its Common and Class B common stock. The increase will be reflected in the Company’s next quarterly dividend payment in April 2025. Albert H. Nahmad, Watsco’s Chairman & CEO stated: “We are pleased to increase dividends to shareholders, reflecting the strength of our 2024 performance and our confidence in the prospects of our business, which is fundamentally supported by our strong balance sheet.” Watsco has paid dividends to shareholders for 51 consecutive years. The Company’s philosophy is to share increasing amounts of cash flow through higher dividends while maintaining a conservative balance sheet with continued capacity to...

Boosts Annual Dividend 11% to $12.00 Per Share Entrepreneurial Culture, Transformational Technologies and Debt-Free Balance Sheet Continue to Produce Results and Provide Long-Term Opportunities MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) reported fourth quarter and full year 2024 results and provided commentary on current business trends, technology innovation and long-term growth drivers. Watsco also announced today an 11% increase to its annual dividend to $12.00 per share effective with its next regular dividend payment in April 2025. Watsco is the leading distributor in the HVAC/R marketplace, serving over 375,000 contractors, technicians and installers annually from 691 locations across the U.S., Canada and Latin America. Since entering distribution in 1989 through the end of 2024, the compounded annual...

CINCINNATI, Feb. 18, 2025 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen and fifty-two weeks ended December 28, 2024. Fourth Quarter 2024 Highlights (Thirteen Weeks Ended December 28, 2024)Net sales increased 0.5% to $349.6 million compared to $347.8 million in the prior year quarter Net loss totaled $(1.2) million, or $(0.01) per diluted share, compared to net loss of $(10.1) million, or $(0.05) per diluted share, in the prior year quarter Adjusted diluted EPS1 was $0.10 per diluted share compared to $0.10 per diluted share in the prior year quarter Adjusted EBITDA1 totaled $56.3 million compared to $54.4 million in the prior year quarter On February 13, 2025, Jon Michael Adinolfi,...

BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (the “Company” or “DraftKings”) today announced the launch of syndication for a proposed senior secured term loan B credit facility (the “Term Loan B”) in an aggregate principal amount of $500 million. The consummation of the Term Loan B is subject to market and other conditions. DraftKings intends to utilize the net proceeds of the Term Loan B for general corporate purposes. About DraftKings DraftKings Inc. is a digital sports entertainment and gaming company created to be the Ultimate Host and fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming, and digital media. Headquartered in Boston and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated...

WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at the JW Marriott Grande Lakes, Orlando, FL, on Tuesday, March 4, 2025, at 3:25 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology,...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025. “We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea®, as better...